Zevra Therapeutics (ZVRA) Revenue & Revenue Breakdown
Zevra Therapeutics Revenue Highlights
Latest Revenue (Y)
$23.61M
Latest Revenue (Q)
$25.88M
Main Segment (Y)
License
Zevra Therapeutics Revenue by Period
Zevra Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $23.61M | -14.02% |
| 2023-12-31 | $27.46M | 162.58% |
| 2022-12-31 | $10.46M | -63.50% |
| 2021-12-31 | $28.65M | 115.61% |
| 2020-12-31 | $13.29M | 3.50% |
| 2019-12-31 | $12.84M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Zevra Therapeutics generated $23.61M in revenue during NA 2024, up -14.02% compared to the previous quarter, and up 183.91% compared to the same period a year ago.
Zevra Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $25.88M | 26.86% |
| 2025-03-31 | $20.40M | 69.40% |
| 2024-12-31 | $12.04M | 225.93% |
| 2024-09-30 | $3.69M | -16.95% |
| 2024-06-30 | $4.45M | 29.90% |
| 2024-03-31 | $3.42M | -74.09% |
| 2023-12-31 | $13.22M | 356.55% |
| 2023-09-30 | $2.90M | -65.82% |
| 2023-06-30 | $8.47M | 194.20% |
| 2023-03-31 | $2.88M | 24.15% |
| 2022-12-31 | $2.32M | -19.31% |
| 2022-09-30 | $2.87M | 121.08% |
| 2022-06-30 | $1.30M | -67.21% |
| 2022-03-31 | $3.96M | 53.56% |
| 2021-12-31 | $2.58M | 31.40% |
| 2021-09-30 | $1.97M | -83.61% |
| 2021-06-30 | $11.99M | -1.08% |
| 2021-03-31 | $12.12M | 412.13% |
| 2020-12-31 | $2.37M | 22.91% |
| 2020-09-30 | $1.93M | -72.13% |
| 2020-06-30 | $6.91M | 230.68% |
| 2020-03-31 | $2.09M | 51.82% |
| 2019-12-31 | $1.38M | -88.00% |
| 2019-09-30 | $11.46M | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | - |
Zevra Therapeutics generated $25.88M in revenue during Q2 2025, up 26.86% compared to the previous quarter, and up 755.65% compared to the same period a year ago.
Zevra Therapeutics Revenue Breakdown
Zevra Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 |
|---|---|
| License | $18.00M |
Latest
Zevra Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 |
|---|---|---|
| License | $1.30M | $1.20M |
Latest
Zevra Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: License (100.00%).
Zevra Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARCT | Arcturus Therapeutics | $152.31M | $28.30M |
| NAGE | Niagen Bioscience | $99.60M | $29.13M |
| RGNX | REGENXBIO | $83.33M | $21.36M |
| MGTX | MeiraGTx | $33.28M | $1.93M |
| ZVRA | Zevra Therapeutics | $23.61M | $25.88M |
| CMPX | Compass Therapeutics | - | - |
| SVRA | Savara | - | - |
| KALV | KalVista Pharmaceuticals | - | $1.43M |
| MLTX | MoonLake Immunotherapeutics | - | - |
| ATXS | Astria Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |